Correlation Between Madrigal Pharmaceuticals and Stoke Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and Stoke Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and Stoke Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Madrigal Pharmaceuticals and Stoke Therapeutics, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and Stoke Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of Stoke Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and Stoke Therapeutics.

Diversification Opportunities for Madrigal Pharmaceuticals and Stoke Therapeutics

-0.04
  Correlation Coefficient

Good diversification

The 3 months correlation between Madrigal and Stoke is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and Stoke Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stoke Therapeutics and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with Stoke Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stoke Therapeutics has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and Stoke Therapeutics go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and Stoke Therapeutics

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 1.26 times more return on investment than Stoke Therapeutics. However, Madrigal Pharmaceuticals is 1.26 times more volatile than Stoke Therapeutics. It trades about 0.13 of its potential returns per unit of risk. Stoke Therapeutics is currently generating about -0.08 per unit of risk. If you would invest  23,640  in Madrigal Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of  9,238  from holding Madrigal Pharmaceuticals or generate 39.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy98.44%
ValuesDaily Returns

Madrigal Pharmaceuticals  vs.  Stoke Therapeutics

 Performance 
       Timeline  
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Stoke Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Stoke Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Madrigal Pharmaceuticals and Stoke Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Madrigal Pharmaceuticals and Stoke Therapeutics

The main advantage of trading using opposite Madrigal Pharmaceuticals and Stoke Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, Stoke Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stoke Therapeutics will offset losses from the drop in Stoke Therapeutics' long position.
The idea behind Madrigal Pharmaceuticals and Stoke Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope